Proliferation of human breast cancer cells and anti-cancer action of doxorubicin and vinblastine are independent of PKC-α

Journal of Cellular Biochemistry

Volumn 101, Issue 2, 2007, Pages 517-528

  Liu, Daniel S D ^a,c   Krebs, Chad E ^a   Liu, Shi J ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cytotoxicity; Doxorubicin; MCF 7 breast cell; Proliferation; Protein kinase C; Vinblastine

Indexed keywords

DOXORUBICIN; PHORBOL DIBUTYRATE; PHORBOL ESTER; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; VINBLASTINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; DOXORUBICIN; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; PHORBOL 12,13-DIBUTYRATE; PROTEIN KINASE C-ALPHA; STAUROSPORINE; VINBLASTINE;

EID: 34247874518     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21202     Document Type: Article

References (35)

1. Blobe GC, Obeid LM, Hannun YA. 1994. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13:411-431.
2. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, Szwedo D, Kaushal GP, Chambers TC. 2003. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66:459-469.
3. Clemens MJ, Trayner I, Menaya J. 1992. The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. J Cell Sci 103:881-887.
4. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS. 1999. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 154:137-144.
5. de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP, Ways DK. 1995. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest 96:1874-1886.
6. Dennis JU, Dean NM, Bennett CF, Griffith JW, Lang CM, Welch DR. 1998. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-α. Cancer Lett 128: 65-70.
7. Goode NT, Hajibagheri MAN, Parker PJ. 1995. Protein kinase C (PKC)-induced PKC down-regulation. J Biol Chem 270:2669-2673.
8. Hug H, Sarre TF. 2005. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 291:329-343.
9. Huigsloot M, Tijdens RB, van de Water B. 2003. Inhibition of protein kinase Cα enhances anticancer agent-induced loss of anchorage-independent growth regardless of protection against apoptosis by Bcl-2. Mol Pharmacol 64:965-973.
10. Jiang XH, Tu SP, Cui JT, Lin MCM, Xia HHX, Wong AVM, Chan AO-O, Yuen MF, Jiang SH, Lam SK, Rung HF, Soh JW, Weinstein IB, Wong BC-Y. 2004. antisense targeting protein kinase C α and β1 inhibits gastric carcinogenesis. Cancer Res 64:5787-5794.
11. Jordan MA, Thrower D, Wilson L. 1991. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212-2222.
12. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS, Davidson NE. 1992. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52:1278-1283.
13. Kochs G, Hummel R, Meyer D, Hug H, Marme D, Sarre TF. 1993. Activation and substrate specificity of the human protein kinase C α and zeta isoenzymes. Eur J Biochem 216:597-606.
14. La Porta CAM, Comolli R. 1997. Activation of protein kinase C-a isoform in murine melanoma cells with high metastatic potential. Clin Exp Metastasis 15:568-579.
15. Laudanna C, Mochly-Rosen D, Liron T, Constantin G, Butcher EC. 1998. Evidence of z protein kinase C Involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J Biol Chem 273: 30306-30315.
16. 2 isoforms by TNF-α and IL-1β in adult rat ventricular myocytes. Am J Physiol 44:H1462-H1472.
17. Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM, Brodie C. 2001. Protein kinase Cα and protein kinase C5 play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 61:4612-4619.
18. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, Schachtele C. 1993. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268:9194-9197.
19. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
20. Nishizuka Y. 1995. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484-496.
21. O'Brian CA, Ward NE, Stewart JR, Chu F. 2001. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer-An evolving story. Cancer Metastasis Rev 20:95-100.
22. Olson EN, Burgess R, Staudinger J. 1993. Protein kinase C as a transducer of nuclear signals. Cell Growth Differ 4:699-705.
23. Rasouly D, Rahamim E, Lester D, Matsuda Y, Lazarovici P. 1992. Staurosporine-induced neurite outgrowth in PC12 cells is independent of protein kinase C inhibition. Mol Pharmacol 42:35-43.
24. Romanova LY, Alexandrov IA, Nordan RP, Blagosklonny MV, Mushinski JF. 1998. Cross-talk between protein kinase C-α (PKC-α) and -δ (PKC-δ): PKC-a elevates the PKC-d protein level, altering its mRNA transcription and degradation. Biochemistry 37:5558-5565.
25. Saraiva L, Fresco P, Pinto E, Goncalves J. 2004. Characterization of phorbol esters activity on individual mammalian protein kinase C isoforms, using the yeast phenotypic assay. Eur J Pharmacol 491:101-110.
26. Sun Xg, Rotenberg SA. 1999. Overexpression of protein kinase ca in MCF-10A human breast cells engenders dramatic alterations in morphology, proliferation, and motility. Cell Growth Differ 10:343-352.
27. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. 2003. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the akt survival pathway. J Biol Chem 278:33753-33762.
28. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F. 1991. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266:15771-15781.
29. Wang XY, Repasky E, Liu HT. 1999. Antisense inhibition of protein kinase ca reverses the transformed phenotype in human lung carcinoma cells. Exper Cell Res 250:253-263.
30. 2- and p53-dependent pathways. J Biol Chem 279:25535-25543.
31. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ. 1995. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95:1906-1915.
32. Wen-Sheng W, Jun-Ming H. 2005. Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2. J Biomed Sci 12:289-296.
33. Whelan RDH, Parker PJ. 1998. Loss of protein kinase C function induces an apoptotic response. Oncogene 16: 1939-1944.
34. Williams CL, Noti JD. 2001. Reduced expression of Wnt-1 and E-cadherin, and diminished beta-catenin stability in MCF-7 breast cancer cells that overexpress protein kinase C-α. Intl J Oncology 19:1227-1233.
35. Young S, Parker PJ, Ullrich A, Stabel S. 1987. Downregulation of protein kinase C is due to an increased rate of degradation. Biochem J 244:775-779.